Literature DB >> 9177434

The common TEL/AML1 rearrangement does not represent a frequent event in acute lymphoblastic leukaemia occuring in children with Down syndrome.

C Lanza1, G Volpe, G Basso, E Gottardi, F Perfetto, V Cilli, M Spinelli, E Ricotti, A Guerrasio, E Madon, G Saglio.   

Abstract

Individuals with constitutional trisomy 21 (Down syndrome) are at increased risk of developing acute leukaemias, both of myeloid and lymphoid lineage. Although the cause of leukaemia in Down syndrome (DS) remains unknown, potential candidate genes include the ones on chromosome 21, and in particular AML1, the rearrangement of which in the t(8,21) is associated with the French-American-British (FAB) classification M2 subtype of acute myeloid leukaemia (AML) in the general population and has been described in Down patients with AML-M2. Recently, a new rearrangement involving AML1, the t(12;21), producing the TEL/AML1 hybrid transcript, has been described by molecular analysis as the most recurrent genetic lesion in childhood acute lymphoblastic leukemia (ALL). In order to investigate whether the t(12;21) could give a molecular clue as to the precise basis of the etiologic association between DS and acute lymphoblastic leukemia, we tested a series of 11 consecutive cases of ALL in DS children for the presence of the TEL/AML1 transcript, by RT-PCR analysis. We report absence of the TEL/AML1 rearrangement among the 11 cases tested. This data may be suggestive of alternative pathways involved in the pathogenesis of ALL in children with constitutional trisomy 21.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9177434     DOI: 10.1038/sj.leu.2400651

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  4 in total

1.  Excellent long-term survival of children with Down syndrome and standard-risk ALL: a report from the Children's Oncology Group.

Authors:  Yousif Matloub; Karen R Rabin; Lingyun Ji; Meenakshi Devidas; Johann Hitzler; Xinxin Xu; Bruce C Bostrom; Linda C Stork; Naomi Winick; Julie M Gastier-Foster; Nyla A Heerema; Eileen Stonerock; William L Carroll; Stephen P Hunger; Paul S Gaynon
Journal:  Blood Adv       Date:  2019-06-11

2.  Down's syndrome and acute lymphoblastic leukaemia: clinical features and response to treatment.

Authors:  J M Chessells; G Harrison; S M Richards; C C Bailey; F G Hill; B E Gibson; I M Hann
Journal:  Arch Dis Child       Date:  2001-10       Impact factor: 3.791

Review 3.  Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome.

Authors:  Sébastien Malinge; Shai Izraeli; John D Crispino
Journal:  Blood       Date:  2009-01-12       Impact factor: 22.113

4.  Treatment outcomes in children with Acute lymphoblastic leukemia with versus without coexisting Down's syndrome: A systematic review and meta-analysis.

Authors:  Wenjun Liao; Ying Liu
Journal:  Medicine (Baltimore)       Date:  2020-07-17       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.